Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

By Einarson Thomas   Machado Marcio   Walker John   Iskedjian Michael   Cremieux Pierre-Yves   Van Audenrode Marc   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1571-1574

Informa Healthcare

Access to resources Recommend Favorite

Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa

By Hymes Jeffrey   Bickimer Tammy   Jackson James H.   Bookhart Brahim K.   Mody Samir H.   Tak Piech Catherine  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1931-1937

Informa Healthcare

Access to resources Recommend Favorite

Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis

By Hoggard Jeffrey   Crouch Thomas   McMurray Stephen   Levine Michael   Prathikanti Radha   Scarlata Debra   Audhya Paul  

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 2023-2030

Informa Healthcare

Access to resources Recommend Favorite

A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease

By Roger Simon D.   Suranyi Michael G.   Walker Rowan G.    

Current Medical Research and Opinion, Vol. 24, Iss. 8, 2008-08 ,pp. : 2181-2187

Informa Healthcare

Access to resources Recommend Favorite

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia

By Ben-Hamadi R.   Duh M. S.   Aggarwal J.   Henckler A.   Mckenzie R. S.   Tak Piech C.  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1677-1682

Informa Healthcare

Access to resources Recommend Favorite